Key result
The patent WO2014043344 describes a novel approach for myostatin inhibition using a modified fibronectin type III domain with potential to treat muscular dystrophies and muscle-related pathologies.
This patent evaluation highlights a novel modified fibronectin type III domain as a potential therapeutic approach for myostatin inhibition in muscular dystrophies.
Novel myostatin blockade patent in MD is hypothesis-generating; clinical trials needed before any therapeutic consideration.
Muscular dystrophies (MD) are commonly characterized by progressive loss of muscle mass and function. It is hypothesized that therapeutic blockade of the TGF-β ligand myostatin, a negative regulator of muscle mass, will stimulate muscle growth and restore muscle function. Although many anti-myostatin targets are currently being pursued in the clinical setting, the efficacies of the tested molecules have shown mixed results. The patent WO2014043344 describes a novel approach for myostatin inhibition using a modified fibronectin type III domain that could potentially be used to treat MD and other muscle-related pathologies.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2015) conducted a review in Muscular dystrophies (MD) and other muscle-related pathologies. Modified fibronectin type III domain (patent WO2014043344) was evaluated. The patent WO2014043344 describes a novel approach for myostatin inhibition using a modified fibronectin type III domain with potential to treat muscular dystrophies and muscle-related pathologies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: